Marker Therapeutics (MRKR) Set to Announce Quarterly Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is anticipated to announce its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($0.1167) per share and revenue of $2.12 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.16. On average, analysts expect Marker Therapeutics to post ($0.64) EPS for the current fiscal year and ($1.23) EPS for the next fiscal year.

Marker Therapeutics Trading Up 10.9%

NASDAQ MRKR opened at $0.99 on Tuesday. Marker Therapeutics has a 12 month low of $0.84 and a 12 month high of $2.46. The stock has a market cap of $16.51 million, a price-to-earnings ratio of -2.42 and a beta of 1.65. The company’s 50 day moving average is $1.08 and its two-hundred day moving average is $1.34.

Analyst Upgrades and Downgrades

MRKR has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Weiss Ratings raised shares of Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 19th. Finally, HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.